Eli Lilly announced on September 15, 2026 that it will unveil Phase 2 data for eloraTZP — a combination of the selective amylin receptor agonist eloralintide and the GIP/GLP-1 agonist tirzepatide — at the 62nd EASD Annual Meeting in Milan later this month. It is the first Phase 2 readout for the compound, and it arrives alongside Phase 3 retatrutide data at the same conference.
The number that has circulated so far comes from Phase 1b: adding eloralintide 3 mg to tirzepatide 5 mg produced 17% weight loss over 16 weeks, against 10% for tirzepatide 5 mg alone. That is a 7-point gap at a low tirzepatide dose and a short duration, which is why the Phase 2 readout is drawing attention.
Research-context information only. EloraTZP and eloralintide are investigational compounds not approved by the FDA, and neither is available through research-peptide vendors. Doses and outcomes described below come from published clinical trial disclosures. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
What Lilly Is Presenting
The EASD meeting runs September 28 to October 2, 2026. Lilly's cardiometabolic slate spans four compounds, with three EASD-sponsored symposia stacked on September 30 and October 1:
| Session | Date (CEST) | Compound | Data |
|---|---|---|---|
| Amylins in diabetes symposium | Sept 30, 4:30–5:30 p.m. | eloraTZP | Phase 2, obesity/overweight + type 2 diabetes |
| Retatrutide symposium | Sept 30, 8:30–9:30 a.m. | Retatrutide | Phase 3 (TRIUMPH-2) |
| Tirzepatide symposium | Sept 30, 8:30–9:30 a.m. | Tirzepatide | SURPASS-CVOT |
| Orforglipron symposium | Oct 1, 8:30–9:15 a.m. | Orforglipron | Phase 3 (ACHIEVE program) |
EloraTZP is the only genuinely new entry on that list. The others extend programs with published readouts: TRIUMPH-2 reported 20.8% weight loss and a 1.6-point A1C reduction at 80 weeks in adults with obesity and type 2 diabetes, and SURPASS-CVOT reported an 8% lower risk of three-point major adverse cardiovascular events for tirzepatide versus dulaglutide (HR 0.92; 95.3% CI 0.83–1.01).
Lilly calls eloraTZP "triple-acting," which is worth unpacking. Retatrutide is a single peptide that binds GIP, GLP-1, and glucagon receptors. EloraTZP reaches three receptor systems too, but through two separate molecules and with amylin replacing glucagon as the third arm. Glucagon agonism raises energy expenditure; amylin agonism works on satiety and gastric signaling. Same headline count, different biology.
The Phase 1b Data Behind the Headline
The 17%-versus-10% figure comes from a dose-ranging Phase 1b package that ran several parallel cohorts. The fuller picture reported from those cohorts:
16-week cohort (eloralintide added to tirzepatide 5 mg):
| Arm | Mean Weight Change |
|---|---|
| Placebo + tirzepatide 5 mg | −10.0% |
| Eloralintide 3 mg + tirzepatide 5 mg | −17.0% |
| Eloralintide 6 mg + tirzepatide 5 mg | −18.2% |
| Eloralintide 9 mg + tirzepatide 5 mg | −20.5% |
24-week cohort (monotherapy arms versus combination):
| Arm | Mean Weight Change |
|---|---|
| Double placebo | −0.5% |
| Eloralintide 9 mg alone | −14.2% |
| Tirzepatide 15 mg alone | −16.4% |
| Eloralintide 9 mg + tirzepatide 15 mg | −25.5% |
The 24-week cohort is the more informative one, because it carries both monotherapy comparators. Eloralintide alone reached −14.2% and tirzepatide alone −16.4%, while the combination reached −25.5% — more than either arm, though less than their arithmetic sum. A longer 32-week cohort layered eloralintide onto tirzepatide 15 mg and reported up to −29.0%, but that arm is the weakest evidence in the package: only a handful of participants completed it, and small-completer arms routinely overstate effect size.
Reported tolerability followed the class pattern. Adverse events were predominantly gastrointestinal and characterized as mild to moderate. Dropouts clustered in the higher eloralintide arms and in the longer cohorts, which is the signal worth watching when the Phase 2 numbers land — a combination that adds 7 points of weight loss but loses a third of participants is a different product than one that holds them.
These are Phase 1b cohorts of roughly 12 to 16 participants per arm with baseline BMIs of 32.8 and 30.5. Phase 2 exists precisely to test whether those numbers survive larger, longer, more heterogeneous enrollment. The preclinical groundwork was presented at ADA 2026, where eloralintide combined with tirzepatide produced greater weight loss than either agent alone in diet-induced obese rats (abstract 3082-LB).
What This Means for the Research Market
EloraTZP itself changes nothing about availability. Eloralintide is an investigational Lilly molecule with no approval and — unlike retatrutide — no established gray-market supply. It is not stocked by research-peptide vendors, and a fixed combination product is further out still. Nobody is sourcing eloraTZP.
What the data does is validate a thesis the research market has already been acting on: pairing an amylin agonist with an incretin agonist produces more weight loss than either class alone. Lilly's own 24-week cohort is the cleanest published demonstration of that — two monotherapy arms and a combination arm in the same trial, with the combination clearly ahead of both.
That same pairing already exists in the research market in a different form. Cagrilintide is the amylin analog that research vendors actually stock, and it is the compound the amylin-plus-incretin stacking discussion has centered on. Our retatrutide + cagrilintide stack cluster documents how that combination has been reported and dosed, and the cagrilintide dosing guide covers the amylin side on its own.
For readers comparing vendor sourcing on the compounds that are actually listed, Best Tirzepatide Vendors and Best Cagrilintide Vendors rank in-stock sources on price per milligram, third-party certificate-of-analysis testing, and reputation. Current vendor discounts across the recommended list are aggregated on the deals page.
This article contains affiliate links; The Peptide Catalog may earn a commission if you purchase through them. Compounds referenced are sold for research use only and are not FDA-approved for human use.
